{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:19:10Z","timestamp":1789021150585,"version":"build-2803163510"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,18]]},"DOI":"10.7759\/cureus.77607","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:48:48Z","timestamp":1737190128000},"source":"Crossref","is-referenced-by-count":2,"title":["Safety and Efficacy of Novel RNA Interference Therapeutic Agent Zilebesiran in People With Hypertension: A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Vanshika","family":"Singh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A","family":"Qidwai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shailendra K","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajoy","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineeta","family":"Tewari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Maheshwari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.19043","article-title":"Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015","volume":"317","author":"Forouzanfar MH","year":"2017","unstructured":"Forouzanfar MH, Liu P, Roth GA, et al.. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990-2015. JAMA. 2017, 317:165-82. 10.1001\/jama.2016.19043","journal-title":"JAMA"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1000058","article-title":"The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors","volume":"6","author":"Danaei G","year":"2009","unstructured":"Danaei G, Ding EL, Mozaffarian D, Taylor B, Rehm J, Murray CJ, Ezzati M. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors. PLoS Med. 2009, 6:e1000058. 10.1371\/journal.pmed.1000058","journal-title":"PLoS Med"},{"key":"ref3","unstructured":"Hypertension. (2024). Accessed. October 30, 2024: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hypertension."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.19590","article-title":"Treatment of hypertension: a review","volume":"328","author":"Carey RM","year":"2022","unstructured":"Carey RM, Moran AE, Whelton PK. Treatment of hypertension: a review. JAMA. 2022, 328:1849-61. 10.1001\/jama.2022.19590","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacbts.2021.04.004","article-title":"Antisense inhibition of angiotensinogen with Ionis-AGT-l(rx): results of Phase 1 and Phase 2 studies","volume":"6","author":"Morgan ES","year":"2021","unstructured":"Morgan ES, Tami Y, Hu K, et al.. Antisense inhibition of angiotensinogen with Ionis-AGT-l(rx): results of Phase 1 and Phase 2 studies. JACC Basic Transl Sci. 2021, 6:485-96. 10.1016\/j.jacbts.2021.04.004","journal-title":"JACC Basic Transl Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208391","article-title":"Zilebesiran, an RNA interference therapeutic agent for hypertension","volume":"389","author":"Desai AS","year":"2023","unstructured":"Desai AS, Webb DJ, Taubel J, et al.. Zilebesiran, an RNA interference therapeutic agent for hypertension. N Engl J Med. 2023, 389:228-38. 10.1056\/NEJMoa2208391","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref9","article-title":"A Language and Environment for Statistical Computing","author":"R Core Team","year":"2024","unstructured":"R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria; 2024."},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0728","article-title":"RNA interference with Zilebesiran for mild to moderate hypertension: the Kardia-1 randomized clinical trial","volume":"331","author":"Bakris GL","year":"2024","unstructured":"Bakris GL, Saxena M, Gupta A, et al.. RNA interference with Zilebesiran for mild to moderate hypertension: the Kardia-1 randomized clinical trial. JAMA. 2024, 331:740-9. 10.1001\/jama.2024.0728","journal-title":"JAMA"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness LA","year":"2021","unstructured":"McGuinness LA, Higgins JP. Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2021, 12:55-61. 10.1002\/jrsm.1411","journal-title":"Res Synth Methods"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2005.01.011","article-title":"A summary of the effects of antihypertensive medications on measured blood pressure","volume":"18","author":"Wu J","year":"2005","unstructured":"Wu J, Kraja AT, Oberman A, et al.. A summary of the effects of antihypertensive medications on measured blood pressure. Am J Hypertens. 2005, 18:935-42. 10.1016\/j.amjhyper.2005.01.011","journal-title":"Am J Hypertens"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.122.18731","article-title":"Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease","volume":"79","author":"Cruz-L\u00f3pez EO","year":"2022","unstructured":"Cruz-L\u00f3pez EO, Ye D, Wu C, Lu HS, Uijl E, Mirabito Colafella KM, Danser AH. Angiotensinogen suppression: a new tool to treat cardiovascular and renal disease. Hypertension. 2022, 79:2115-26. 10.1161\/HYPERTENSIONAHA.122.18731","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.059","article-title":"Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease","volume":"98","author":"Ferrario CM","year":"2006","unstructured":"Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006, 98:121-8. 10.1016\/j.amjcard.2006.01.059","journal-title":"Am J Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2024.102411","article-title":"Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS)","volume":"49","author":"Maryam","year":"2024","unstructured":"Maryam, Varghese TP, B T. Unraveling the complex pathophysiology of heart failure: insights into the role of renin-angiotensin-aldosterone system (RAAS) and sympathetic nervous system (SNS). Curr Probl Cardiol. 2024, 49:102411. 10.1016\/j.cpcardiol.2024.102411","journal-title":"Curr Probl Cardiol"},{"key":"ref16","unstructured":"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Zilebesiran used as add-on therapy in patients with hypertension not adequately controlled by a standard of care antihypertensive medication. (2024). Accessed. November 4, 2024: https:\/\/clinicaltrials.gov\/study\/NCT05103332."},{"key":"ref17","unstructured":"A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Zilebesiran used as add-on therapy in adult patients with high cardiovascular risk and hypertension not adequately controlled by standard of care. (2024). Accessed. November 4, 2024: https:\/\/clinicaltrials.gov\/study\/NCT06272487."},{"key":"ref18","unstructured":"A phase 1\/2, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the safety, tolerability, efficacy, pharmacodynamics, and pharmacokinetics of Zilebesiran in Japanese patients with mild to moderate hypertension. (2024). Accessed. November 4, 2024:  https:\/\/clinicaltrials.gov\/study\/NCT06423352."},{"key":"ref19","unstructured":"A randomized, double-blind, placebo-controlled, dose-ranging multicenter study to evaluate the efficacy and safety of AlN-Agt01 in patients with mild-to-moderate hypertension. (2024). Accessed. November 4, 2024: https:\/\/clinicaltrials.gov\/study\/NCT04936035."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/330113-safety-and-efficacy-of-novel-rna-interference-therapeutic-agent-zilebesiran-in-people-with-hypertension-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:48:52Z","timestamp":1737190132000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/330113-safety-and-efficacy-of-novel-rna-interference-therapeutic-agent-zilebesiran-in-people-with-hypertension-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.77607","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1,18]]}}}